Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2005 9
2006 7
2007 7
2008 8
2009 5
2010 13
2011 9
2012 4
2013 3
2014 5
2015 7
2016 2
2017 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. Among authors: halpern a. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Pfeffer MA, et al. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. N Engl J Med. 2015. PMID: 26630143 Free article. Clinical Trial.
Why are anti-obesity drugs stigmatized?
Halpern B, Halpern A. Halpern B, et al. Among authors: halpern a. Expert Opin Drug Saf. 2015 Feb;14(2):185-9. doi: 10.1517/14740338.2015.995088. Epub 2014 Dec 20. Expert Opin Drug Saf. 2015. PMID: 25529104
Combinations of drugs in the Treatment of Obesity.
Halpern B, Oliveira ES, Faria AM, Halpern A, Melo ME, Cercato C, Mancini MC. Halpern B, et al. Among authors: halpern a. Pharmaceuticals (Basel). 2010 Jul 27;3(8):2398-2415. doi: 10.3390/ph3082398. Pharmaceuticals (Basel). 2010. PMID: 27713360 Free PMC article. Review.
Pharmacological treatment of obesity.
Mancini MC, Halpern A. Mancini MC, et al. Among authors: halpern a. Arq Bras Endocrinol Metabol. 2006 Apr;50(2):377-89. doi: 10.1590/s0004-27302006000200024. Epub 2006 May 23. Arq Bras Endocrinol Metabol. 2006. PMID: 16767304 Review.
Impact of adiposity on immunological parameters.
Moulin CM, Marguti I, Peron JP, Rizzo LV, Halpern A. Moulin CM, et al. Among authors: halpern a. Arq Bras Endocrinol Metabol. 2009 Mar;53(2):183-9. doi: 10.1590/s0004-27302009000200010. Arq Bras Endocrinol Metabol. 2009. PMID: 19466211 Review.
84 results